PFE · 10-Q · 2026Q3 · Full report
Metsera Acquisition Synergies
PFIZER INC · 2026-11-03 · Importance 52 · Surprise 42 · In source text
Following the November 2025 acquisition of Metsera, Pfizer expects approximately $600 million in annual cost synergies by the end of 2026. The one-time costs to generate those synergies are expected to total approximately $700 million. Pfizer expects to incur the costs primarily from 2025 through 2027 as it establishes an appropriate cost structure for the combined company.
Key facts
- Pfizer expects approximately $600 million of annual cost synergies from its Metsera acquisition by the end of 2026, with approximately $700 million of one-time costs incurred primarily from 2025 through 2027. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | committed | +3.1% | Pfizer expects approximately $600 million of annual cost synergies from its Metsera acquisition by the end of 2026, with approximately… |